Peritumoral Radiomics and Predicting Treatment Response | Oncology | JAMA Network Open | JAMA Network
[Skip to Navigation]
Sign In
Views 1,388
Citations 0
Invited Commentary
September 10, 2020

Peritumoral Radiomics and Predicting Treatment Response

Author Affiliations
  • 1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
JAMA Netw Open. 2020;3(9):e2016125. doi:10.1001/jamanetworkopen.2020.16125

Esophageal cancer is a common malignant neoplasm with a poor prognosis, causing more than 400 000 deaths worldwide every year. Neoadjuvant chemoradiotherapy (neoadjuvant CRT) followed by surgical treatment has been associated with an overall survival benefit compared with surgical treatment alone and has become a standard treatment for locally advanced esophageal cancer. Overall, approximately one-quarter to one-half of patients with esophageal cancer who receive neoadjuvant CRT will achieve pathological complete response after treatment. However, on an individual level, tumor response to neoadjuvant CRT is highly heterogenous. It has been challenging to predict the likelihood of pathological complete response for a given patient prior to treatment initiation.

To address this unmet need, the study by Hu et al1 used a radiomics approach to develop an imaging signature for predicting response to neoadjuvant CRT of esophageal cancer in a multi-institutional study. Hu and colleagues extracted radiomics features from intratumoral and peritumoral regions on baseline computed tomography scans and then examined a combination of these features to compare several different machine learning models. The models based on intratumoral or peritumoral features alone had similar performance for predicting pathological complete response, with results for area under the curve of 0.730 (95% CI, 0.609-0.850) for intratumoral and 0.734 (95% CI, 0.613-0.854) for peritumoral, while the combined model, consisting of 7 intratumoral and 6 peritumoral features, achieved a significantly better accuracy of 0.852 (95% CI, 0.753-0.951) in an independent test set. Hu and colleagues further showed that the discriminative power of the radiomics model was independent of several clinical parameters, including sex, smoking and drinking history, and tumor stage and grade.

Radiomics has been used extensively in oncology to discover novel prognostic and predictive imaging signatures for various cancers.2 The term radiomics refers to the extraction of quantitative features from regions of interest in medical images, which can then be used for classification and prediction. Traditionally, this approach has been focused on the bulk analysis of the primary tumor. Because invasion is a hallmark of cancer, it is conceivable that regions surrounding the tumor (ie, peritumoral regions) contain complementary and useful information about the disease. Several recent studies have successfully demonstrated the proof of principle for using peritumoral radiomics to predict treatment response in breast3 and cervical4 cancers. The study by Hu et al1 provides additional evidence for the value of peritumoral radiomics, specifically in the context of response prediction in esophageal cancer.

The advent of big data and deep learning suggests that these handcrafted features, which rely heavily on domain expertise and prior knowledge, could be automated, and initial results are encouraging. A 2020 study that used a class activation map for visualization of deep learning networks5 identified regions surrounding the primary tumor as important areas for prediction of prognosis in gastric cancer. This suggests that deep learning could recapitulate the findings of radiomics studies and provide further support for the utility of peritumoral evaluation.

Another notable aspect of the study by Hu et al1 is that the researchers integrated imaging and gene expression data to perform a radiogenomics analysis; this analysis may provide important insight into the biological underpinnings of the radiomics model. They found that the imaging signature was associated with adaptive immunity, such as lymphocyte infiltration and interferon signaling in the tumor. This finding is consistent with a 2017 study6 demonstrating the critical role of a tumor’s immune microenvironment in determining therapy response and outcomes. Interestingly, a recently developed radiomic signature combines features of intratumoral and peritumoral regions, allowing the noninvasive evaluation of the immune microenvironment in gastric cancer and predicting prognosis and chemotherapy response.7

The study by Hu et al1 used high-quality rigorous radiomics research. In addition to the use of intratumoral and peritumoral features and integrative radiogenomics analysis, a strength of this work is its multi-institution cohort study design, with independent validation of the radiomics model (albeit with a relatively small number of patients for validation). The study used a test-retest strategy to avoid feature redundancy and minimize interobserver variability. Method details were provided for feature harmonization, selection, and evaluation to ensure a robust prediction model. These are important attributes of reproducible radiomics research that may help move the field forward.

The ability to reliably predict treatment response may improve the selection of patients who are most likely to benefit from neoadjuvant CRT while sparing others from the toxic effects associated with the treatment. The radiomic signature developed by Hu et al1 provides a promising direction to follow in pursuing this goal.

However, before the practical implementation of this method can occur, several issues and questions need to be addressed. First, the generalizability of the imaging signature across different computed tomography scanners and imaging protocols should be rigorously assessed. Second, because the study investigated multiple machine learning classifiers with varying levels of accuracy, it will be important to choose a final model, which will be locked before it is ready for further validation in prospective studies. Third, the patient population in this study comes from 1 geographic region in southern China, where most esophageal cancers are squamous cell carcinomas. In Western countries, this pattern is reversed, and most esophageal cancers are adenocarcinomas. Given the different response rates to neoadjuvant CRT of these 2 histological subtypes, it will be interesting to test how this signature works for adenocarcinomas. Despite the need for further validation, the study by Hu et al1 represents a step forward toward an individualized approach to the treatment of esophageal cancer.

Back to top
Article Information

Published: September 10, 2020. doi:10.1001/jamanetworkopen.2020.16125

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Li R. JAMA Network Open.

Corresponding Author: Ruijiang Li, PhD, Department of Radiation Oncology, Stanford University School of Medicine, 1070 Arastradero Rd, Palo Alto, CA 94304 (

Conflict of Interest Disclosures: Dr Li reported receiving grants from the US National Institutes of Health outside the submitted work.

Hu  Y, Xie  C, Yang  H,  et al.  Assessment of intratumoral and peritumoral computed tomography radiomics for predicting pathological complete response to neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma.   JAMA Netw Open. 2020;3(9):e2015927. doi:10.1001/jamanetworkopen.2020.15927Google Scholar
Gillies  RJ, Kinahan  PE, Hricak  H.  Radiomics: images are more than pictures, they are data.   Radiology. 2016;278(2):563-577. doi:10.1148/radiol.2015151169 PubMedGoogle ScholarCrossref
Braman  N, Prasanna  P, Whitney  J,  et al.  Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)–positive breast cancer.   JAMA Netw Open. 2019;2(4):e192561. doi:10.1001/jamanetworkopen.2019.2561 PubMedGoogle Scholar
Sun  C, Tian  X, Liu  Z,  et al.  Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: a multicentre study.   EBioMedicine. 2019;46:160-169. doi:10.1016/j.ebiom.2019.07.049 PubMedGoogle ScholarCrossref
Jiang  Y, Jin  C, Yu  H,  et al.  Development and validation of a deep learning CT signature to predict survival and chemotherapy benefit in gastric cancer: a multicenter, retrospective study.   Ann Surg. Published online January 6, 2020. doi:10.1097/SLA.0000000000003778 PubMedGoogle Scholar
Li  B, Cui  Y, Diehn  M, Li  R.  Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non–small cell lung cancer.   JAMA Oncol. 2017;3(11):1529-1537. doi:10.1001/jamaoncol.2017.1609 PubMedGoogle ScholarCrossref
Jiang  Y, Wang  H, Wu  J,  et al.  Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer.   Ann Oncol. 2020;31(6):760-768. doi:10.1016/j.annonc.2020.03.295 PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words